TxTB are few.
Methods. Renal allograft recipients were studied prospecthe causes of morbidity and mortality among these patively for 3.1 (0 to 13.9) median (range) years for incidence, tients [1] . Powerful immunosuppression prevents organ manifestations, risk factors, and prognosis for post-TxTB.
rejections at the expense of increasing the incidence of Kaplan-Meier analysis was used to study the survival rates.
ambient and opportunistic infections. It is estimated that
The extended Cox proportional model for time-dependent coin the last decade, at least 50% of the Indian population variates was used to measure the risk factors when the hazard was nonuniform.
above the age of 20 years is infected with the tubercle was 2.5 (P ϭ 0.0311) and 1.9 (P ϭ 0.0430) times at Յ6 and Յ12
However, most data on this important disease are from months, respectively, compared with patients on prednisolone retrospective or short-term studies.
plus azathioprine (PRED ϩ AZA). The risk of post-TxTB in
The present report documents the incidence, distributhe presence of diabetes mellitus, chronic liver disease, and tion, risk factors, and prognosis of post-TxTB in a large other co-existing infections [including deep mycoses, cytomegalovirus (CMV), Pneumocystis carinii pneumonia (PCP), nocohort drawn from all parts of India and surrounding cardia] was 2.2 (P ϭ 0.0011), 1.7 (P ϭ 0.0010) and 2.4 (P Ͻ countries who were followed up prospectively for over excluded from the analysis of risk factors for post-TxTB.
post-TxTB Ͼ2 years (P ϭ 0.0036), chronic liver disease Ͼ6 years (P ϭ 0.0457), PTDM Ͼ5 years (P ϭ 0.0729), diabetes
The mean age of this patient cohort was 32.8 Ϯ 11 (SD) mellitus (P ϭ 0.0091), human lymphocyte antigen match Յ1 years, and 1033 (82.6%) were males.
antigen (P ϭ 0.0134), two to three antigens (P ϭ 0.0448), and the presence of other co-existing infections (P Ͻ 0.0001).
Conclusions. Cyclosporine therapy is associated with early METHODS post-TxTB. Diabetes mellitus and chronic liver disease are risk factors for post-TxTB. The occurrence of both pre-TxTB and ever possible these were examined using histopathology,
Abbreviations are: PRED ϩ AZA, prednisolone ϩ azathioprine; PTDM, microscopy, and culture.
post-transplant diabetes mellitus; CsA group, most received cyclosporine immunoAll patients with post-TxTB were treated with ATT suppression for a year.
for 18 months and were followed up with lifelong, secondary isoniazid prophylaxis. Until 1990, patients received streptomycin for three months, pyrazinamide for the assumption of proportionality. In the analysis of facnine months, and ethambutol ϩ isoniazid for 18 months.
tors affecting the outcome, there was a similar violation Rifampicin was used in a few patients on PRED ϩ AZA, of proportionality with risk factors for death, namely, doubling the dose of PRED to compensate for cytopost-TxTB, chronic liver disease, and post-transplant dichrome P-450 induction. Since 1994, ofloxacin has been abetes mellitus (PTDM), defined as fasting blood sugar used for nine months and pyrazinamide for the first three Ͼ120 mg/dL and two-hour post-prandial blood sugar months along with ethambutol and isoniazid. Primary Ͼ200 mg/dL or two elevated levels of either measurechemoprophylaxis was not used during this period except ment. These variables were analyzed with extended Cox as part of a trial [5] . Empirical ATT was given when model for time-dependent covariates using heavy side radiological evidence suggested TB or for pyrexia of functions along with the other time-independent variunknown origin (PUO) when other tests were negative.
ables that were significant at 20% level of significance Statistical methods in the univariate Cox regression model [6] . The data Descriptive statistics, cumulative calendar-year inciwere analyzed using SPSS for Windows software. dence, and actuarial incidence were calculated for postTxTB. Kaplan-Meier analysis and log-rank statistics RESULTS were used to study the association between explanatory Of the remaining 1251 patients, the prevalence of postvariables and post-TxTB.
TxTB was 13.3% (N ϭ 166) over a median (range) folIn analyzing the risk factors for the occurrence of low-up period of 3.1 (0 to 13.9) years. The patient and tuberculosis and for death, the variables were checked donor characteristics, risk factors, and outcome are shown for proportionality assumptions. In the analysis of the occurrence of post-TxTB, immunosuppression violated in Table 1 . The distribution of liver disease, diabetes melli- with those without the disease (19.6%, P ϭ 0.0055).
Lymph node 8 (4.8)
However, the distribution of graft loss or renal failure
Skin and soft tissue 7 (4.2) Intestine 5 (3.0) (creatinine Ͼ3.5 mg/dL) was similar in both groups.
Central nervous system 3 (1.8)
The calendar-year incidence of post-TxTB in renal is shown in Figure 1A . There was a year-to-year variation, and the three-year moving average indicates a lower incidence during the latter half of the study period as compared with 1980s and early 1990s. There is a declining incidence of post-TxTB with the passing years after trans-(25.9%) patients of whom 26 had a PUO that responded to treatment. The remaining 17 had exudative, lymphocytic plantation (Fig. 1B) .
The distribution of lesions of post-TxTB is shown in effusions, or radiological lesions highly suggestive of TB. In two patients, the diagnosis of post-TxTB was possible Table 2 . Pleuropulmonary involvement was seen in 48.2% and disseminated tuberculosis in 19.3% of patients. Three only with post-mortem examination. The probability of patients surviving without post-TxTB was 93.5, 86, and fourths of patients had histopathological or microbiological proof of tuberculosis. Empirical ATT was given to 43 82.6% on CsA immunosuppression and 95.6, 83.4, and The distribution of risk factors and demographic de-95% CI, 0.83 to 2.69, P ϭ 0.1839) were found to be tails of patients who died and of others are detailed in significant. Further multivariate modeling with these Table 4 . The probability of survival with pre-TxTB was variables demonstrated that the risk of post-TxTB in the 86.7, 66.7, and 66.7% and with post-TxTB was 92.5, 68.3, presence of diabetes mellitus and chronic liver disease and 52.5% at 1, 5, and 10 years, respectively. In compariwas 2.2-and 1.7-fold, respectively. The relative risk of son, the survival in patients without TB was 91.1, 76.7, other co-existing infections (deep mycoses, CMV, PCP, and 70.8%, respectively (P ϭ 0.0091). On univariate nocardia) was 2.4 times in the presence of post-TxTB.
analysis, the factors associated with death were the recipThe risk of post-TxTB on CsA was 2.5 times at Յ6 months ient age (HR, 1.03; 95% CI, 1.02 to 1.04, P Ͻ 0.0001), and 1.9 times at 0 to 12 months when compared with HLA Յ1 antigen match (HR, 1.62; 95% CI, 1.06 to 2.47, patients on PRED ϩ AZA. However, the risk for post-P ϭ 0.0236), PRED ϩ AZA immunosuppression (HR, TxTB Ͼ12 months on PRED ϩ AZA was 1.5 times as 1.66; 95% CI, 1.32 to 2.08, P Ͻ 0.0001), pre-TxTB (HR, compared with those who had received CsA immunosup-1.37, 95% CI, 0.94 to 1.98, P ϭ 0.0925), post-TxTB Ͼ2 pression (Table 3) . years (HR, 2.25; 95% CI, 1.50 to 3.37, P ϭ 0.0001), The outcome of patients with post-TxTB was studied chronic liver disease Ͼ6 years (HR, 3.33; 95% CI, 1.43 in comparison with those who did not develop the disease.
to 7.73, P ϭ 0.0051), diabetes mellitus (HR, 2.50; 95% Of the 166 patients who developed post-TxTB, 53 pa-CI, 1.80 to 3.46, P Ͻ 0.0001), PTDM Ͼ5 years (HR, 2.35; tients died and of these deaths, 17 (32%) were from 95% CI, 1.17 to 4.73, P ϭ 0.0165), and the presence of post-TxTB. An associated co-existence of other infecother co-existing infections (HR, 2.91; 95% CI, 2.21 to tions (deep mycoses, CMV, PCP, nocardia, and hepato-3.84, P Ͻ 0.0001). Analyzing these time-dependent varitropic viral infections with chronic liver disease) contributed to the deaths of 11 (65%) of these 17 patients.
ables using the extended Cox model for death as the India [3] . The death rate depends on the study duration of the cohort following transplantation. Later post-transplant years witness a smaller number of cases of TB but outcome variable, the significant risk factors were posthigher death rates. Post-TxTB occurring after two years TxTB Ͼ2 years, chronic liver disease Ͼ6 years, diabetes of transplantation independently carries a 1.8-fold risk mellitus, PTDM Ͼ5 years, HLA mismatches, and presof death as compared with patients who did not develop ence of other co-existing infections (Table 5) .
the disease. Post-TxTB that occurs away from medical observation beyond two years is again undetected until DISCUSSION the patient is often moribund. In contrast, post-TxTB occurring within the first two years does not increase The prevalence of post-TxTB in the developed Westrisk of death. ern nations ranges from 1 to 4% [7, 8] , while reports from Tuberculosis occurring two years after transplantation India show a much higher prevalence. This remarkable as well as pre-transplant TB are risk factors for death difference in prevalence is a result of high endemic TB after the transplant, as are diabetes mellitus, PTDM, in India. There is a variation in prevalence within the chronic liver disease, and the occurrence of other coexistcountry, as 11.8% were found in northern India [3] , ing infections such as deep mycoses, CMV, PCP, and 13.3% in the southern area (present study), and 8.3%
nocardia. The hazard of death with chronic liver disease in a previous report [9] . This is in part a result of the and post-transplant DM varies with time. Chronic liver varying proportion of patients receiving empirical therdisease independently increases the risk of death threeapy; for example, empirical therapy was reported in 39%
fold at six years after transplantation. Unabated viral of post-TxTB patients [3] , while in the present study, proliferation, hepatic fibrosis, and subsequent liver dys-26% patients received empirical therapy. The duration function take approximately six years to manifest in our of TB after transplantation in our cohort altered the population. Post-transplant DM that occurs five years prevalence of post-TxTB, because the disease incidence after transplantation doubles the risk of death. This is declines in the late post-transplant years.
related to a period of unrecognized hyperglycemia ocThe calendar-year incidence of post-TxTB is imporcurring in some patients, which results in a higher susceptant baseline data for practitioners of transplant meditibility and poor response to infections. cine in developing countries to help the early detection These observations are unique to vast developing counof an unusually high incidence of post-TxTB, occurring due to unusual exposure or risk factors.
tries such as India where appropriate medical care is not
